ACRO BIOMEDICAL changed its Leadership on September 2, 2026, appointing Shao-Hsiang Shih as director and chairman and Jing-Zhou Chen as CEO and CFO. Yu-Ting Su resigned from her director, chairman and CEO roles, effective when a successor was appointed. Investors now have named executives for the company’s principal leadership positions.
Key Highlights
- Yu-Ting Su’s resignation was not related to any disagreement with ACRO BIOMEDICAL.
- Shao-Hsiang Shih has worked at Century Publishing Co. since 2010 and became its administrative management director in 2020.
- Jing-Zhou Chen has led Dream Born Co. Ltd. since March 2025 and previously managed a cloud-kitchen Franchise business.
ACRO BIOMEDICAL CO. LTD. (OTC: ACBM) changed its senior leadership on September 2, 2026, naming Shao-Hsiang Shih chairman and director and Jing-Zhou Chen chief executive officer and chief financial officer. The appointments took effect the same day, while Yu-Ting Su’s departure from the director, chairman and CEO positions became effective when a successor was appointed.
Yu-Ting Su resigned from all three positions without citing any disagreement with ACRO BIOMEDICAL.
Investor Insights
Shih graduated from National Taipei University’s Department of Statistics in 2003 and earned a master’s degree from Fo Guang University’s Graduate Institute of Buddhist Studies in 2018. He has pursued doctoral studies in Eastern Humanistic Thought at Huafan University since 2018.
FAQs
Q: Who is the new chairman of ACRO BIOMEDICAL?
A: Shao-Hsiang Shih became ACRO BIOMEDICAL’s director and chairman on September 2, 2026. He has held management roles at Century Publishing Co. since 2010.
Q: Who is ACRO BIOMEDICAL’s new CEO and CFO?
A: Jing-Zhou Chen was appointed chief executive officer and chief financial officer effective September 2, 2026. He has led Dream Born Co. Ltd. since March 2025.
Q: Why did Yu-Ting Su leave ACRO BIOMEDICAL?
A: Yu-Ting Su resigned as director, chairman and CEO of ACRO BIOMEDICAL. The announcement said her resignation did not result from disagreement with the company.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.